OncLive TV

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Richard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Gretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.

Christine Bestvina, MD, discusses the emerging role of neoadjuvant chemoimmunotherapy in lung cancer.

Tomer Mark, MD, discusses establishing minimal residual disease (MRD) as a surrogate marker for survival in multiple myeloma.

Charu Aggarwal, MD, MPH, discusses the significance of the phase 3 IMpower010 trial in patients with PD-L1–positive non–small cell lung cancer.

Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.

Cristina Gasparetto, MD, discusses how to manage keratopathy associated with treatment with belantamab mafodotin-blmf in patients with multiple myeloma.

Alexander J. Lazar, MD, PhD, discusses the current state of diagnosis and treatment in desmoid tumors.

Bilal A. Siddiqui, MD, discusses selecting between available antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Shikha Jain, MD, FACP, discusses the need to enroll heterogenous patient populations to clinical trials in colorectal cancer.

Matthew S. McKinney, MD, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

John M. Burke, MD, discusses findings from the phase 3 POLARIX trial in patients with newly diagnosed diffuse large B-cell lymphoma.

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

Benjamin Heyman, MD, discusses future therapeutic directions in mantle cell lymphoma.

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

Noelle V. Frey, MD, MSCE, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia that were presented at the 2021 ASH Annual Meeting & Exposition.

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

Sattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. 

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.

Matthew S. McKinney, MD, cellular therapy specialist, hematologic oncologist, hematologist (malignant), Duke Health, discusses emerging therapeutic strategies in mantle cell lymphoma (MCL).

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.